TLX597-Tx Dosimetry Data Signal Shift in RLT Dose Strategy

Telix Pharmaceuticals has presented initial dosimetry results from the OPTIMAL-PSMA Phase 2 trial of TLX597-Tx at the 2026 International Prostate Cancer Symposium in Lugano, Switzerland, with findings that carry direct implications for how next-generation radioligand therapies are dosed, manufactured, and submitted for regulatory review. Reduced off-target uptake in the salivary glands and kidneys, combined with higher tumor uptake relative to existing PSMA-targeting RLTs, positions TLX597-Tx as a candidate capable of supporting dose intensification without proportional increases in organ toxicity risk -- a profile that will inform both clinical development specifications and GMP manufacturing parameters for contract and in-house production teams.

TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is a small molecule PSMA-targeting RLT candidate. The OPTIMAL-PSMA trial is an open-label, multi-center, randomized, investigator-initiated study led by Professor Louise Emmett at St Vincent's Hospital in Sydney, enrolling 120 men with metastatic castration-resistant prostate cancer (mCRPC) on a 2:1 randomization. The intensified dosing regimen delivers 8.5 GBq per cycle, administered on day 1, day 3, and day 15, followed by 10-weekly dosing for three additional cycles. This schedule is designed to maximize radiation dose to tumor lesions during periods of peak vulnerability.

Manufacturing and QA context: Dose-intensified RLT regimens place heightened demands on radiopharmaceutical production, including tighter radionuclidic purity controls, accelerated release testing timelines, and sterility assurance protocols aligned with 21 CFR Part 211 and applicable ICH Q10 quality system expectations. The favorable dosimetry profile reported for TLX597-Tx may ultimately support broader therapeutic window claims in regulatory submissions, a factor QA directors and regulatory affairs leads at both sponsors and CDMOs should track as the RLT manufacturing sector scales.

Telix is developing two distinct prostate cancer therapeutic programs: TLX591-Tx, a radio antibody-drug conjugate currently in Phase 3 for mCRPC, and TLX597-Tx, intended for earlier-stage metastatic hormone-sensitive prostate cancer (mHSPC). Based on the OPTIMAL-PSMA dosimetry data, Telix is initiating OPTIMAL-E, a Phase 2 study in androgen pathway-sensitive prostate cancer. Professor Emmett stated the goal is to identify a dose regimen that delivers deeper and longer responses without increasing toxicity. Dr. David N. Cade, Group Chief Medical Officer at Telix, noted the data support further study in mHSPC and reinforce a strategy of stage-tailored PSMA-targeting therapy selection.

Source: Telix Pharmaceuticals press release, April 30, 2026. Trial data presented at IPCS 2026, Lugano, Switzerland.